Pinned Tweet
What's better than one flagship AI publication? Two in the same year!
I enjoyed discussing 1910's latest AI models — PEGASUS™ for macrocyclic peptide design and CANDID-CNS™ for small molecule BBB penetration with @GENbio for @1910_ai
GEN Article here: genengnews.com/topics/artifi…
The kind of aura you have when you're the CEO of the world's first and only trillion-dollar pharma 🫡
Last year, I was at dinner with @nabihasaklayen, and was stunned when she said: "I want to build a vending machine that prints organs. So, at the click of a button, instead of a soda, out comes a kidney, liver, or heart personalized for you."
This is Step 1 to that future 👇🏾
In partnership with Vinod Khosla (@vkhosla), I’m proud to introduce Reservoir.
Billionaires have owned their cells for years. Starting today, you can too.
Sign up today: withreservoir.com
I'm proud to be an early investor in this generational company that is revolutionizing chip manufacturing for frontier AI. After 7 years in stealth, @keplercompute launches today as a Series D company with $468M raised, and a cracked team!
Congratulations, @dolaoseb! 👏
We are proud to announce @keplercompute. Our mission is unlock computing for everyone by pushing memory and logic to the limits of physics.
Our team co-led one of the industry's first 3D chip-stacking technologies, has led and scaled seven generations of DRAM and multiple logic designs into billions of chips. We built the world's first commercial physical synthesis tool and techniques at the heart of the logic design industry and solved long standing challenges in ferroelectrics, invented beyond CMOS logic devices. We would love to work with you to reinvent chip manufacturing here in America.
Memory is the biggest binding constraint on AI compute. Today we come out of stealth after a 7 year bet on this problem - introducing a new frontier of AI memories - that approach the bandwidth per watt of SRAM and go up to 10x beyond the capacity of SRAM and HBM.
We raised $468m, built a dedicated fab and our AI memories sample this year and ramp to production next year. We are allocated for 2027 and will be scaling in America by 2028.
We are open for business get in touch to work together. We are also growing the group of Keplerians and would love to work with you.
Learn More @ Kepler: keplercompute.com/
Read our story in @WIRED: wired.com/story/a-new-dollar…
I'm thrilled to be speaking at @SynBioBeta, on a panel exploring the New AI Operating Model for Pharma Partnerships. I'll be representing @1910_ai alongside @chaidiscovery, @nablabio, @NOETIK_ai, @enveda, and @theinformation
#SynBioBeta2026, #AIxBio, #Partnerships
Jen Asher, Ph.D. retweeted
Learn more about 1910’s flagship AI models:
PEGASUS™ Featured Publication in J. Med. Chem.: lnkd.in/etbvf5VH
CANDID-CNS™ Publication in JCIM: lnkd.in/gWn2fYiP
Read the media exclusive in GEN Edge: lnkd.in/eyr_qb9f
Honored to be in the company of AI x Bio women I admire!
The future of frontier AI in Pharma is here, and @1910_ai is leading it!
Our founder @JenAsherPhD was featured in a spotlight on 5 women shaping AI x Bio — highlighting Jen's work at 1910, where we're building an AI-native biotech transforming drug discovery with our ITO™ Platform.
Read the article: techlifesci.com/p/five-women…
Great exclusive interview with @GENbio discussing the latest frontier AI models from @1910_ai -- PEGASUS™ for macrocyclic peptide design and CANDID-CNS™ for small molecule BBB penetration!
To partner, please contact [email protected]
1910 Unlocks Macrocyclic Peptide Drugs Using PEGASUS AI Model
PEGASUS generates permeable macrocyclic peptides, offering new promise for a modality that can combine the properties of a biologic in a pill
@jenasherphd @1910_ai
#AI #drugdiscovery #peptides
hubs.li/Q03ZRTp70
Today, @1910_ai is thrilled to announce the publication of PEGASUS™, a state-of-the-art AI model for de novo design and optimization of macrocyclic peptides.
▪️Paper: pubs.acs.org/doi/10.1021/acs…
▪️Press Release: businesswire.com/news/home/2…
▪️ BD: To partner on PEGASUS™, [email protected]
Today, @1910_ai publishes CANDID-CNS™, a SOTA AI model that predicts BBB penetration by unlocking Beyond-Rule-of-5 (bRo5) chemical space and stereochemistry of small molecules.
- Paper: pubs.acs.org/doi/10.1021/acs…
- Press Release: businesswire.com/news/home/2…
- To partner with 1910 on CANDID-CNS™, please contact [email protected]
Jen Asher, Ph.D. retweeted
I'm excited to announce that @1910_ai's CANDID-CNS™ AI model is now published in the Journal of Chemical Information and Modeling (JCIM) @ACSPublications, marking an important milestone in validating AI-driven approaches to CNS drug discovery.
Paper: pubs.acs.org/doi/10.1021/acs…
At today's #AIDDDSummit, AI in drug discovery is on full display. It's why we built @1910_ai's ITO™ platform —integrating massive multimodal data, frontier AI models, and high-throughput lab automation for AI-enabled drug discovery. Check it out at 1910.ai/platform.
Jen Asher, Ph.D. retweeted
We're entering a new chapter of transformative pharmaceutical partnerships and building a pipeline of innovative medicines. Watch to learn more from our Founder @JenAsherPhD about our new mission to Make Every Pharma Company an AI Company™.
